Understand the source comparison
Pinealon Legal 2026 Status: Comparison Table
Purchase for institutional research (in-vitro studies, cell culture, animal models) Legal Institutional purchase order, research use agreement, CoA from supplier Low. Compliant with FDA 503B frameworks Fully compliant if supplier is FDA-registered 503B facilit
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Purchase for institutional research (in-vitro studies, cell culture, animal models)
- Legal
- Institutional purchase order, research use agreement, CoA from supplier
- Low. Compliant with FDA 503B frameworks
- Fully compliant if supplier is FDA-registered 503B facility and peptide labeled 'research use only'
- Purchase for IRB-approved clinical trial
- Active IND application, IRB approval documentation, GMP-certified peptide source
- Low. Legally protected under clinical trial exemptions
- Requires FDA authorization but operationally straightforward with proper documentation
- Purchase for personal cognitive enhancement or anti-aging use
- Not compliant
- None applicable
- High. Violates FDA unapproved drug marketing guidance
- Functions as off-label self-administration of unapproved drug. Not defensible under current frameworks
- Sale with therapeutic claims ('boosts brain function', 'anti-aging peptide')
- Illegal
- N/A
- Very high. Explicit FDA enforcement target
- Direct violation of FDA enforcement guidance; warning letters issued consistently since 2023
- Compounding by 503A pharmacy for patient-specific prescription
- Legal (narrow pathway)
- Valid prescription from licensed physician, documented medical necessity
- Moderate. Requires prescriber attestation that no FDA-approved alternative exists
- Technically legal but rarely used for Pinealon due to lack of clinical indication in standard practice